Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Chemistry gets substantial grants
2013-06-10

 

At the experimental setup of the high temperature reduction oven for research in heterogeneous catalysis are, front from left: Maretha Serdyn (MNS Cluster prestige PhD bursar), Nceba Magqi (Sasol employee busy with his MSc in Chemistry) and Dr Alice Brink (Formal MNS Cluster postdoctoral fellow and lecturer in Inorganic Chemistry); back Profs Jannie Swarts (Head: Physical Chemistry), André Roodt, and Ben Bezuidenhoudt (Sasol Professor in Organic and Process Chemistry).
10 June 2013

Three research groups in the Department of Chemistry received substantial grants to the value of R4,55 million. The funding includes bursaries for students and post-doctoral fellows, mobility grants, running costs and equipment support, as well as dedicated funds for two young scientists in the UFS Prestige Scholar Programme, Drs Lizette Erasmus and Alice Brink.

The funding comes from Sasol, the THRIP programme of the National Research Foundation (NRF) and PetLabs Pharmaceuticals for the overarching thrust in Organic Synthesis, Homogeneous and Heterogeneous Catalysis. The programme has a broad focuse on different fundamental and applied aspects of process chemistry. Research groups of Profs Andreas Roodt (Inorganic), Jannie Swarts (Physical) and Ben Bezuidenhoudt (Organic / Process), principal members of the focus area of (Green) Petrochemicals in the Materials and Nanosciences Strategic Research Cluster (MNS Cluster) will benefit from the grant.

This funding was granted based on the continued and high-level outputs by the groups, which resulted in more than 40 papers featuring in international chemistry publications in merely the past year. A few papers also appeared in the top experimental inorganic chemistry journal from the American Chemical Society, Inorganic Chemistry. These high-impact papers address important issues in catalysis under the UFS Material and Nanosciences Research Cluster initiative, as well as other aspects of fundamental chemistry, but with an applied approach and focus.

Prof Andreas Roodt, Distinguished Professor and Chairperson of the Department of Chemistry, said the grants will enable the three research groups to move forward in their respective research areas associated with petrochemicals and other projects, and enable additional students in the department to benefit from it. It will also ensure that these groups can continue and maintain their research on different molecular and nano-scale materials. Current experiments include conversions under extremely high gas pressures (typical 100 times that in motor car tyres). This takes place at the molecular level and at preselected nano-surfaces, to convert cheaper feed-stream starting materials into higher value-added products for use as special additives in gasoline and other speciality chemicals.

The funding support forms part of the Hub-and-Spoke initiative at Sasol under which certain universities and specifically the UFS Department of Chemistry have been identified for strategic support for research and development. The department and the UFS gratefully acknowledge this continued and generous support from all parties concerned.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept